MedPath

Drug-eluting Balloon vs. Conventional Balloon in the Treatment of (re)Stenosis - a Randomized Prospective Study

Not Applicable
Completed
Conditions
Peripheral Artery Stenosis
Peripheral Artery Occlusive Disease
Peripheral Artery Restenosis
Registration Number
NCT03023098
Lead Sponsor
Helsinki University Central Hospital
Brief Summary

The purpose of this study is to determine whether the use of drug-eluting balloons is effective in the treatment of (re)stenosis in bypass vein grafts.

Detailed Description

Drug-eluting devices have proved beneficial in the treatment of stenosis in native coronary and lower limb arteries. Stenosis and restenosis is a known problem in bypass vein grafts, and drug-eluting devices might be beneficial in this field as well.

In the procedure a conventional balloon is passed through the stenosis which is then dilated. After this patients are randomized before a second dilatation with either a conventional balloon or a drug-coated balloon.

The stenosis is evaluated preoperatively and followed up by means of ultrasound by a vascular technician. Follow-up will end at 12 months.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
57
Inclusion Criteria
  • Any venous bypass with stenosis warranting intervention
Exclusion Criteria
  • Previous PTA with drug-eluting balloon, thrombolysis, coagulopathy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
TLR (Target lesion revascularization)12 months

Any reintervention to the same lesion.

Graft occlusion0-12 months

Occlusion of the bypass graft

Secondary Outcome Measures
NameTimeMethod
Major amputation0-12 months

Above or below knee amputation of the treated leg

Death0-12 months

Trial Locations

Locations (1)

Helsinki University Hospital

🇫🇮

Helsinki, Finland

Helsinki University Hospital
🇫🇮Helsinki, Finland

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.